Michel Michaelides, MD, discusses phase 3 DRAGON results showing that oral tinlarebant slowed atrophic lesion growth by about 36% in adolescents with Stargardt disease.

Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews sura-vec, 4D-150 and ixo-vec, 3 nAMD gene therapies in phase 3 with readouts expected over the next 12 months.

A single intravitreal injection improved acuity in Stargardt disease; a randomized trial in geographic atrophy is planned.

At EURETINA 2026, Jordi Monés, MD, PhD, outlined the rationale for gene-agnostic optogenetic therapy MCO-010 to restore vision in Stargardt disease and geographic atrophy.

At EURETINA 2026, David Steel reviewed registry evidence on gas and silicone oil tamponades for retinal detachment repair and outlined novel tamponade agents in his Kreissig Award Lecture.

Host Deborah Ristvedt, DO, welcomes Dr. Mathews to discuss the relationships, passions, and intentional choices that have shaped her career as a cornea, cataract, and refractive surgeon, dry eye expert, and educator.

Sunir Garg, MD, FACS, previews DME and dry AMD data, free papers, and surgical sessions at AAO 2026.